1. Which of the following correctly distinguishes ertapenem from imipenem with respect to the requirement for a dehydropeptidase I (DHP-I) inhibitor?
A) Both imipenem and ertapenem require co-administration with cilastatin because both are efficiently hydrolyzed by DHP-I on the renal tubular brush border, generating nephrotoxic metabolites
B) Ertapenem requires co-administration with cilastatin only when used for urinary tract infections, because DHP-I is expressed at high levels in the renal tubular lumen and would otherwise inactivate ertapenem before it reaches urine
C) Ertapenem does not require a DHP-I inhibitor because it is not significantly hydrolyzed by DHP-I, whereas imipenem is rapidly inactivated by renal DHP-I and must be co-formulated with cilastatin to preserve urinary drug concentrations and prevent nephrotoxic metabolite generation
D) Ertapenem requires betamipron rather than cilastatin as its DHP-I inhibitor because cilastatin's binding affinity for DHP-I is insufficient to protect ertapenem's longer-chain C-2 substituent from hydrolysis
E) Neither imipenem nor ertapenem requires a DHP-I inhibitor in current clinical formulations because modern synthesis techniques produce DHP-I-stable ring conformations in both drugs
ANSWER: C
Rationale:
Imipenem is the only carbapenem in clinical use that requires co-administration with a DHP-I inhibitor (cilastatin). Imipenem's specific chemical structure — particularly its C-6 substituents — makes it an efficient substrate for dehydropeptidase I (DHP-I), the zinc metalloprotease on the brush border of proximal renal tubular cells. Without cilastatin, DHP-I hydrolyzes a substantial fraction of filtered imipenem, generating nephrotoxic ring-opened metabolites and reducing urinary drug concentrations. Ertapenem, meropenem, and doripenem are inherently resistant to DHP-I hydrolysis due to structural differences at C-1 and C-2 that render them poor substrates for the enzyme; none of these agents requires a DHP-I inhibitor in their formulation. This distinction is clinically relevant because imipenem-cilastatin is a fixed combination (the cilastatin cannot be removed or dose-adjusted independently), while ertapenem is a single-agent formulation with simpler administration.
Option A: Option A is incorrect; only imipenem, not ertapenem, is hydrolyzed by DHP-I to a clinically meaningful extent — the statement that both require cilastatin is false.
Option B: Option B is incorrect; ertapenem does not require cilastatin even for urinary tract infections — it is not a DHP-I substrate regardless of the site of infection.
Option D: Option D is incorrect; betamipron is used with panipenem (a carbapenem used in Japan) as a nephrotoxicity inhibitor, not a DHP-I inhibitor for ertapenem; ertapenem has no such co-formulation requirement.
Option E: Option E is incorrect; imipenem continues to require cilastatin in all current clinical formulations; the need for DHP-I inhibition is an inherent pharmacological property of imipenem's structure, not a manufacturing limitation that has been overcome.
2. Meropenem is preferred over imipenem for treatment of gram-negative meningitis and in patients with known seizure disorders. Which structural and pharmacological feature of meropenem most directly accounts for its lower seizurogenic potential compared to imipenem?
A) Meropenem carries a 1-beta-methyl group at C-1 of the bicyclic ring that reduces interaction with the inhibitory GABA-A (gamma-aminobutyric acid type A) receptor picrotoxin-binding site, substantially lowering its capacity to reduce inhibitory neurotransmission and raise seizure risk
B) Meropenem has lower CNS penetration than imipenem due to higher protein binding, so brain tissue concentrations during standard dosing remain below the threshold required for GABA-A receptor antagonism
C) Meropenem undergoes more rapid renal clearance than imipenem, limiting drug accumulation in patients with normal renal function and preventing CNS drug levels from reaching seizurogenic concentrations
D) Meropenem is co-formulated with cilastatin, which competitively blocks GABA-A receptors in the CNS and provides a direct neuroprotective effect against imipenem-class seizure induction
E) Meropenem selectively binds PBP2 rather than PBP3 in gram-negative pathogens, and this altered PBP selectivity reduces the generation of pro-convulsant cell wall breakdown products that are responsible for imipenem's seizure risk
ANSWER: A
Rationale:
The structural basis for meropenem's reduced seizurogenic potential relative to imipenem is the 1-beta-methyl substituent at C-1 of the carbapenem bicyclic ring. This methyl group reduces the molecule's affinity for the picrotoxin-binding site within the GABA-A receptor chloride channel — the same site through which imipenem (and its ring-opened metabolites) exerts its inhibitory effect on GABA-mediated chloride influx. By reducing GABA-A antagonism, meropenem has substantially lower intrinsic capacity to lower the seizure threshold. Clinically, meropenem is the standard carbapenem of choice whenever CNS pathology is present, seizure history exists, or renal impairment predisposes to imipenem accumulation.
Option B: Option B is incorrect; meropenem does not have higher protein binding than imipenem — in fact both have relatively low protein binding (imipenem approximately 20%, meropenem approximately 2%); reduced CNS penetration is not the mechanism of meropenem's lower seizure risk.
Option C: Option C is incorrect; while renal clearance kinetics differ somewhat between the agents, rapid renal clearance is not the pharmacological basis for meropenem's reduced seizurogenic potential — the mechanism is structural interaction with GABA-A receptors, not clearance rate.
Option D: Option D is incorrect; meropenem does not contain cilastatin; it does not require a DHP-I inhibitor; and cilastatin has no GABA-A receptor antagonist properties or neuroprotective mechanism.
Option E: Option E is incorrect; the seizurogenic mechanism of imipenem is not mediated through PBP selectivity or cell wall breakdown products — it is a direct GABA-A receptor pharmacological effect of the parent drug and its hydrolysis products.
3. A Klebsiella pneumoniae isolate is confirmed by PCR to produce KPC (Klebsiella pneumoniae carbapenemase). Which of the following correctly classifies KPC and identifies the beta-lactamase inhibitors that are capable of inhibiting it?
A) KPC is a class B zinc-dependent metallo-beta-lactamase; it is inhibited by avibactam and vaborbactam because both agents chelate the zinc cofactors required for its hydrolytic mechanism
B) KPC is a class C AmpC-type cephalosporinase that has acquired carbapenem-hydrolyzing activity through promoter upregulation; it is inhibited by tazobactam but not by avibactam or vaborbactam
C) KPC is a class D OXA-type serine carbapenemase; it is inhibited by avibactam at standard concentrations but not reliably by vaborbactam, which lacks class D inhibitory activity
D) KPC is a class A serine carbapenemase that uses a catalytic serine residue for hydrolysis; it is inhibited by avibactam (a DBO inhibitor), vaborbactam (a boronic acid inhibitor), and relebactam (a DBO inhibitor), all of which form covalent or tight interactions with the class A active-site serine
E) KPC is a class A serine carbapenemase that is inhibited by avibactam but not by vaborbactam or relebactam because only DBO-class inhibitors achieve sufficient periplasmic concentrations to overcome KPC's high hydrolytic turnover rate
ANSWER: D
Rationale:
KPC (Klebsiella pneumoniae carbapenemase) is a class A serine beta-lactamase — one of four Ambler structural classes based on the hydrolytic mechanism. Class A enzymes (also including TEM, SHV, CTX-M, and SME-type carbapenemases) use a two-step acylation-deacylation mechanism centered on a catalytic serine residue. All three currently approved beta-lactamase inhibitors used in novel CRE combinations inhibit KPC: avibactam (a diazabicyclooctane, DBO) forms a reversible covalent carbamyl ester with the class A serine; vaborbactam (a cyclic boronic acid) forms a reversible covalent tetrahedral adduct with the same serine; relebactam (also a DBO, structurally related to avibactam) inhibits class A and class C enzymes by the same DBO carbamylation mechanism. All three share the critical feature of requiring a catalytic serine for their inhibitory mechanism, which is why none inhibits class B metallo-beta-lactamases (NDM, VIM, IMP).
Option A: Option A is incorrect; KPC is not a class B enzyme and does not use zinc; it is a class A serine enzyme.
Option B: Option B is incorrect; KPC is not an AmpC (class C) enzyme; it is a class A carbapenemase with a distinct structure and is not reliably inhibited by tazobactam at clinically achievable concentrations.
Option C: Option C is incorrect; KPC is class A, not class D; OXA-type carbapenemases (class D) include OXA-48, OXA-23, and OXA-58 — a distinct enzyme family.
Option E: Option E is incorrect; both vaborbactam and relebactam do inhibit KPC effectively; the limitation of all three inhibitors is not KPC's turnover rate but rather their shared inability to inhibit class B metallo-beta-lactamases.
4. Which of the following most precisely characterizes the antibacterial spectrum of aztreonam as a monobactam?
A) Aztreonam covers aerobic gram-negative bacilli and gram-positive cocci but lacks activity against anaerobes, making it suitable as monotherapy for most community-acquired infections provided anaerobic coverage is not required
B) Aztreonam is active exclusively against aerobic gram-negative bacilli, including Enterobacteriaceae and Pseudomonas aeruginosa; it has no activity against gram-positive organisms of any species and no activity against anaerobes of any species
C) Aztreonam covers all gram-negative organisms including both aerobic and anaerobic gram-negative rods, but has no activity against any gram-positive organism due to the absence of suitable PBP targets in gram-positive cell walls
D) Aztreonam has a broad spectrum equivalent to carbapenems against gram-negative organisms but is distinguished by its lack of gram-positive coverage; like carbapenems it covers ESBL-producing Enterobacteriaceae reliably as monotherapy
E) Aztreonam covers aerobic gram-negative bacilli and facultative anaerobes but not obligate anaerobes, making it appropriate for complicated intra-abdominal infections when combined only with a gram-positive agent
ANSWER: B
Rationale:
Aztreonam's spectrum is defined by its high selectivity for PBP3 (penicillin-binding protein 3, the cell division transpeptidase) of aerobic gram-negative bacteria. This PBP3 selectivity, combined with aztreonam's requirement for gram-negative outer membrane penetration to reach its periplasmic target, produces a drug with activity strictly restricted to aerobic gram-negative bacilli — primarily Enterobacteriaceae (Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) and non-fermenters (Pseudomonas aeruginosa, some Acinetobacter). Gram-positive organisms lack suitable PBP3 homologs with meaningful aztreonam affinity, and their absence of an outer membrane prevents aztreonam from reaching any target. Obligate anaerobes lack the outer membrane required for aztreonam penetration and their PBP targets have no aztreonam affinity; aztreonam has zero anaerobic activity. This absolute lack of gram-positive and anaerobic coverage is the critical clinical limitation that makes aztreonam monotherapy inappropriate for polymicrobial infections such as intra-abdominal infections from bowel perforation.
Option A: Option A is incorrect; aztreonam has no gram-positive activity whatsoever — the statement that it covers gram-positive cocci is false.
Option C: Option C is incorrect; aztreonam does not cover anaerobic gram-negative rods (such as Bacteroides fragilis); its spectrum is limited to aerobic gram-negatives regardless of morphology or Gram stain appearance.
Option D: Option D is incorrect; aztreonam is hydrolyzed by ESBLs and is unreliable as monotherapy for serious ESBL-producing infections — the comparison to carbapenems for ESBL coverage is not accurate.
Option E: Option E is incorrect; aztreonam has no activity against obligate anaerobes or against the aerobic gram-positives that are also major contributors to intra-abdominal infection; describing it as covering "facultative anaerobes but not obligate anaerobes" mischaracterizes the relevant clinical gap.
5. NDM (New Delhi metallo-beta-lactamase) is one of the most clinically challenging resistance determinants in gram-negative bacteriology. Which of the following correctly classifies NDM and explains why currently approved beta-lactamase inhibitors fail against it?
A) NDM is a class A serine carbapenemase; avibactam fails against NDM because NDM's class A active site has an unusually bulky acyl-enzyme intermediate that prevents avibactam from completing its carbamylation reaction
B) NDM is a class C AmpC-type enzyme; it is not inhibited by avibactam because avibactam's DBO ring is too large to fit into the narrow AmpC active site of NDM variants found in Klebsiella pneumoniae
C) NDM is a class D OXA-type carbapenemase; avibactam does not inhibit it because NDM's class D active site serine is protected by a specific carboxylation modification that prevents DBO carbamylation
D) NDM is a class B zinc-dependent metallo-beta-lactamase; avibactam inhibits NDM weakly but vaborbactam does not, because avibactam's DBO ring can interact with one of NDM's two zinc ions while the boronic acid moiety of vaborbactam cannot
E) NDM is a class B zinc-dependent metallo-beta-lactamase that hydrolyzes beta-lactams using zinc-activated water rather than a catalytic serine; avibactam, vaborbactam, and relebactam all require a serine residue for their covalent inhibitory mechanism and therefore cannot inhibit NDM or any other class B enzyme
ANSWER: E
Rationale:
NDM (New Delhi metallo-beta-lactamase) belongs to Ambler class B — the metallo-beta-lactamases — a mechanistically distinct group that employs one or two zinc ions to coordinate and activate a hydroxide ion for direct nucleophilic attack on the beta-lactam carbonyl, bypassing any serine-based catalytic pathway. All three currently approved beta-lactamase inhibitors used in CRE combinations (avibactam, vaborbactam, relebactam) function by forming covalent or tight-binding interactions with the active-site serine of class A, C, or D serine beta-lactamases. Because NDM has no catalytic serine — only zinc-coordinated water as its nucleophile — none of these inhibitors has any mechanistic foothold on the NDM active site. This pharmacological incompatibility is absolute and is shared by all three inhibitors: it is not a matter of concentration, ring size, or affinity but a fundamental mechanistic mismatch. VIM and IMP are the other clinically important class B enzymes with the same inhibitor-resistant profile.
Option A: Option A is incorrect; NDM is not a class A enzyme; it is a class B metallo-enzyme with no catalytic serine.
Option B: Option B is incorrect; NDM is not a class C AmpC enzyme; AmpC enzymes are serine cephalosporinases found on chromosomes of Enterobacter, Citrobacter, and others — a distinct enzyme family.
Option C: Option C is incorrect; NDM is not a class D OXA-type enzyme; class D includes OXA-48, OXA-23, and OXA-58, which are serine carbapenemases distinct from metallo-enzymes.
Option D: Option D is incorrect; avibactam does not inhibit NDM even weakly through zinc interaction — there is no established interaction between avibactam's DBO scaffold and NDM's zinc cofactors, and no current data support partial or weak inhibition of NDM by avibactam at any clinically achievable concentration.
6. Which combination of pharmacokinetic properties most directly accounts for ertapenem's suitability for once-daily dosing compared to imipenem and meropenem, which require every-6- to every-8-hour dosing?
A) Ertapenem undergoes hepatic metabolism to an active metabolite with a half-life of 12 hours, extending its effective antibacterial duration well beyond the parent drug's own elimination kinetics
B) Ertapenem has a post-antibiotic effect (PAE) of greater than 6 hours against Enterobacteriaceae, allowing bacteriostatic suppression to continue well after plasma concentrations fall below the MIC and eliminating the need for frequent dosing
C) Ertapenem is actively secreted into the bile, creating an enterohepatic recirculation cycle that sustains plasma concentrations throughout the 24-hour dosing interval without the need for repeated intravenous doses
D) Ertapenem has approximately 95% plasma protein binding and a serum half-life of approximately 4 hours — substantially longer than imipenem or meropenem (each approximately 1 hour) — allowing free drug concentrations to remain above the MIC of susceptible pathogens throughout a 24-hour interval at standard once-daily dosing
E) Ertapenem penetrates and concentrates within tissue macrophages, creating an intracellular drug reservoir that releases active drug slowly over 24 hours, maintaining bacterial killing at infected tissue sites between doses
ANSWER: D
Rationale:
Ertapenem's pharmacokinetic profile differs fundamentally from imipenem and meropenem in two interrelated properties. First, ertapenem is approximately 95% bound to plasma proteins (primarily albumin), compared to approximately 20% for imipenem and approximately 2% for meropenem. This extensive protein binding limits the volume of distribution and slows renal clearance, because only the free (unbound) fraction is filtered at the glomerulus. Second, the resulting serum half-life of ertapenem is approximately 4 hours, compared to approximately 1 hour for both imipenem and meropenem. Like all beta-lactams, carbapenems exhibit time-dependent (not concentration-dependent) bactericidal activity; efficacy is determined by the percentage of the dosing interval during which free (unbound) drug concentrations remain above the MIC. Ertapenem's prolonged half-life, arising directly from its high protein binding, sustains adequate free drug time above MIC over a 24-hour interval at the standard 1 g once-daily dose. Imipenem and meropenem's short half-lives necessitate every-6- to every-8-hour dosing to maintain the same pharmacodynamic target.
Option A: Option A is incorrect; ertapenem is not converted to an active metabolite with a 12-hour half-life; it is primarily renally eliminated as unchanged drug and does not undergo hepatic activation.
Option B: Option B is incorrect; beta-lactams as a class have minimal post-antibiotic effects against gram-negative organisms; a PAE greater than 6 hours is not a property of ertapenem and would not alone justify once-daily dosing for a time-dependent agent.
Option C: Option C is incorrect; ertapenem does not undergo significant biliary secretion or enterohepatic recirculation; renal elimination is its primary route.
Option E: Option E is incorrect; ertapenem does not concentrate intracellularly in macrophages or create an intracellular drug reservoir; this is a property of macrolides and fluoroquinolones, not carbapenems.
7. Cefiderocol retains activity against carbapenem-resistant gram-negative pathogens that have lost OprD and other outer membrane porins. Which mechanism allows cefiderocol to penetrate the outer membrane of these porin-deficient organisms?
A) Cefiderocol's extended C-3 cephalosporin side chain is highly lipophilic and dissolves directly through the lipid bilayer of the outer membrane, bypassing the need for any protein channel
B) Cefiderocol is co-administered with a permeabilizer compound that transiently disrupts outer membrane lipopolysaccharide, creating non-specific pores through which the drug diffuses into the periplasm
C) Cefiderocol is conjugated to a catecholate siderophore moiety that chelates ferric iron; the resulting ferric-cefiderocol complex is actively transported across the outer membrane by TonB-dependent iron-uptake transporters, independent of OprD or OmpF porins
D) Cefiderocol binds to the BamA outer membrane protein assembly complex, triggering a conformational change that opens a transient channel through which the drug enters the periplasm
E) Cefiderocol's high negative charge density at physiological pH creates electrostatic repulsion with outer membrane lipopolysaccharide that forces the molecule through lipid-disordered regions of the outer membrane at sites of membrane stress
ANSWER: C
Rationale:
Cefiderocol is a siderophore cephalosporin — a drug class that exploits bacterial iron acquisition mechanisms to achieve outer membrane penetration independent of standard porins. Gram-negative bacteria require iron for survival and have evolved high-affinity iron-uptake systems centered on siderophores (small iron-chelating molecules) and TonB-dependent outer membrane transporter proteins. TonB-dependent transporters actively transport ferric-siderophore complexes across the outer membrane using energy transduced from the inner membrane proton motive force via the TonB-ExbBD complex. Cefiderocol's catecholate siderophore moiety chelates ferric iron (Fe³⁺) in the environment, and the resulting cefiderocol-Fe³⁺ complex is recognized and actively transported inward by these TonB-dependent transporters. This pathway is entirely independent of OprD (the carbapenem porin in Pseudomonas aeruginosa), OmpF, OmpC, and other standard diffusion porins. Once in the periplasm, cefiderocol retains its cephalosporin PBP3-binding activity and is highly stable to all classes of beta-lactamases.
Option A: Option A is incorrect; cefiderocol is not lipophilic in the conventional sense — the siderophore conjugate is hydrophilic; passive lipid bilayer dissolution is not the mechanism.
Option B: Option B is incorrect; cefiderocol is not co-administered with a permeabilizer compound; it is a single-agent formulation that achieves penetration through its intrinsic siderophore conjugate mechanism.
Option D: Option D is incorrect; BamA is an outer membrane beta-barrel assembly factor involved in OMP biogenesis; it does not function as a drug import channel and does not transport cefiderocol.
Option E: Option E is incorrect; electrostatic repulsion from lipopolysaccharide is not a recognized mechanism of outer membrane penetration for any antibiotic; the LPS negative charge generally impedes, not facilitates, penetration of negatively charged molecules.
8. A patient with a well-documented history of anaphylaxis to amoxicillin requires antibiotic therapy for a gram-negative infection. Aztreonam is proposed. Which structural and immunological principle explains why aztreonam carries negligible cross-reactivity risk with penicillins in this patient?
A) Aztreonam is a monobactam containing a single beta-lactam ring without a fused bicyclic ring system; penicillin allergy is mediated against epitopes on the bicyclic beta-lactam-thiazolidine ring and its degradation products, none of which are present in the monocyclic aztreonam structure
B) Aztreonam shares the same core beta-lactam ring as penicillins but the ring is in a trans configuration rather than cis, and penicillin-specific IgE antibodies do not recognize the trans isomer
C) Aztreonam is a pro-drug that is cleaved by serum esterases before it reaches plasma concentrations sufficient to trigger mast cell degranulation, preventing IgE-mediated hypersensitivity regardless of prior penicillin sensitization
D) Aztreonam cross-reactivity with penicillin is negligible because aztreonam is renally cleared before the drug reaches systemic mast cells and basophils at concentrations required for IgE receptor cross-linking
E) Aztreonam's sulfonic acid group on the monocyclic ring creates a negatively charged surface that electrostatically repels IgE antibody binding, regardless of whether the patient's IgE was generated against penicillin or aztreonam epitopes
ANSWER: A
Rationale:
The immunological basis of penicillin allergy rests primarily on IgE sensitization to the penicilloyl major determinant — a hapten formed when the penicillin beta-lactam ring opens and covalently modifies lysine residues on serum proteins, creating the penicilloyl-protein conjugate that stimulates IgE production. This major determinant is structurally defined by the bicyclic beta-lactam-thiazolidine scaffold unique to penicillins. Cephalosporins share a bicyclic structure (beta-lactam fused to a dihydrothiazine ring) and have a historically described but low cross-reactivity with penicillins, largely mediated through shared R1 side chain homology rather than ring structure per se. Aztreonam, as the sole monobactam in clinical use, contains only a single unfused beta-lactam ring — no fused bicyclic system, no thiazolidine ring, no dihydrothiazine ring. The immunogenic epitopes generated from penicillin degradation are structurally absent from aztreonam, explaining the consistently negligible cross-reactivity documented in clinical allergy studies. Aztreonam is considered safe to administer to penicillin-allergic patients.
Option B: Option B is incorrect; the cross-reactivity issue is not about ring configuration (cis vs trans) but about the presence or absence of the bicyclic ring system and its degradation epitopes, which aztreonam lacks entirely.
Option C: Option C is incorrect; aztreonam is not a pro-drug and is not cleaved by serum esterases; it is administered as the active parent molecule.
Option D: Option D is incorrect; aztreonam's renal clearance route does not prevent systemic exposure — it is distributed systemically before renal elimination, and the absence of cross-reactivity is structural, not pharmacokinetic.
Option E: Option E is incorrect; electrostatic repulsion of IgE by a sulfonic acid group is not a recognized immunopharmacological mechanism, and the absence of cross-reactivity is explained by structural epitope absence, not charge interactions.
9. Which of the following correctly identifies the CNS mechanism responsible for imipenem-associated seizures and the patient characteristics that amplify this risk?
A) Imipenem activates voltage-gated sodium channels in cortical neurons in a use-dependent manner, generating repetitive high-frequency action potentials that recruit adjacent neurons into a seizure focus; renal impairment amplifies this risk by increasing the sodium channel-active metabolite fraction in plasma
B) Imipenem competitively inhibits glutamate reuptake transporters in the synaptic cleft, raising extracellular glutamate concentrations and driving excessive NMDA (N-methyl-D-aspartate) receptor activation; this mechanism is amplified in patients with pre-existing excitotoxic CNS injury
C) Imipenem crosses the blood-brain barrier and is converted by neuronal esterases to a ring-opened neurotoxic metabolite that directly depolarizes inhibitory interneurons, silencing them and producing a net excitatory state; this conversion is accelerated in patients with hepatic impairment
D) Imipenem (and its ring-opened hydrolysis products) antagonizes GABA-A receptors at the picrotoxin-binding site within the chloride channel, reducing inhibitory GABAergic neurotransmission and lowering the seizure threshold; risk is amplified by renal impairment (drug accumulation), pre-existing CNS pathology, and prior seizure history
E) Imipenem induces cerebral cytochrome P450 enzyme upregulation in astrocytes, accelerating local metabolism of endogenous GABAergic neurosteroids and reducing brain GABA levels systemically; this effect is amplified in patients receiving concurrent enzyme-inducing anticonvulsants
ANSWER: D
Rationale:
Imipenem's seizurogenic mechanism is well characterized and involves direct pharmacological interaction with GABA-A (gamma-aminobutyric acid type A) receptors, the principal fast inhibitory receptors in the CNS. Imipenem and its ring-opened hydrolysis products interact with the picrotoxin-binding site — a non-competitive blocking site within the GABA-A chloride channel that, when occupied, prevents chloride influx in response to GABA, reducing inhibitory postsynaptic potentials and lowering the seizure threshold. This is the same general mechanism as picrotoxin poisoning. Risk factors for imipenem-associated seizures include: renal impairment (reduced drug clearance leads to higher plasma and CNS drug concentrations), pre-existing CNS disease (meningitis, brain abscess, stroke, or tumor, which disrupt the blood-brain barrier and alter neuronal excitability), prior seizure history, and high imipenem doses. Meropenem's substantially lower seizure risk is attributed to its C-1 beta-methyl group reducing GABA-A interaction.
Option A: Option A is incorrect; imipenem does not activate voltage-gated sodium channels; sodium channel pharmacology is the mechanism of local anesthetics and some antiepileptic drugs, not carbapenems.
Option B: Option B is incorrect; imipenem does not inhibit glutamate reuptake transporters; NMDA receptor-mediated excitotoxicity is not the recognized mechanism of carbapenem neurotoxicity.
Option C: Option C is incorrect; while imipenem does undergo ring opening, the mechanism of neurotoxicity is GABA-A receptor antagonism, not esterase-mediated neuronal depolarization; hepatic esterases are not the key metabolic factor — renal DHP-I is the relevant enzyme.
Option E: Option E is incorrect; imipenem does not induce cerebral cytochrome P450 enzymes or reduce brain GABA levels through neurosteroid metabolism; this is a fabricated mechanism with no pharmacological basis.
10. Which of the following correctly describes the clinical evidence and carbapenemase coverage profile of meropenem-vaborbactam for KPC-producing carbapenem-resistant Enterobacteriaceae (KPC-CRE)?
A) Meropenem-vaborbactam demonstrated superiority over ceftazidime-avibactam for KPC-CRE bacteremia in the TANGO II trial (a randomized controlled trial of meropenem-vaborbactam versus best available therapy); it also covers NDM-CRE through vaborbactam's dual inhibitory mechanism that bridges both serine and metallo-enzyme active sites
B) Meropenem-vaborbactam demonstrated superior 28-day clinical outcomes compared to best available therapy for KPC-CRE infections in the TANGO II trial (a randomized controlled trial of meropenem-vaborbactam versus best available therapy for carbapenem-resistant infections); vaborbactam covers KPC (class A) and AmpC (class C) but not NDM (class B) or OXA-48 (class D)
C) Meropenem-vaborbactam was approved for KPC-CRE on the basis of pharmacokinetic-pharmacodynamic modeling only; no randomized clinical trial comparing it to best available therapy has been completed, and clinical outcome data are extrapolated from the TANGO I trial (a trial of meropenem-vaborbactam in complicated urinary tract infections without carbapenem resistance)
D) Meropenem-vaborbactam covers all four major carbapenemase classes (KPC, NDM, OXA-48, and VIM) because vaborbactam's boronic acid scaffold provides a broad-spectrum inhibitory effect that is less class-dependent than the DBO scaffold of avibactam
E) Meropenem-vaborbactam demonstrated non-inferiority but not superiority to ceftazidime-avibactam for KPC-CRE in the TANGO II trial, and guideline bodies recommend ceftazidime-avibactam over meropenem-vaborbactam as first-line therapy for confirmed KPC-CRE bacteremia
ANSWER: B
Rationale:
Meropenem-vaborbactam (Vabomere) combines meropenem with vaborbactam, a cyclic boronic acid beta-lactamase inhibitor. Vaborbactam inhibits class A serine beta-lactamases (including KPC) and class C AmpC enzymes through reversible covalent tetrahedral adduct formation with the catalytic serine; it does not inhibit class B metallo-beta-lactamases (NDM, VIM, IMP) or class D OXA-type carbapenemases (OXA-48, OXA-23) because these enzymes lack the catalytic serine required for vaborbactam's mechanism. The TANGO II trial (a randomized, multicenter, open-label trial comparing meropenem-vaborbactam to best available therapy in patients with carbapenem-resistant gram-negative infections, including KPC-CRE) demonstrated superior 28-day all-cause mortality and higher rates of clinical cure with meropenem-vaborbactam for KPC-CRE infections. This was one of the first prospective randomized trials to demonstrate outcome superiority with a novel CRE-directed agent.
Option A: Option A is incorrect; vaborbactam does not cover NDM — it has no inhibitory mechanism against class B metallo-beta-lactamases; the TANGO II trial compared meropenem-vaborbactam to best available therapy, not to ceftazidime-avibactam specifically.
Option C: Option C is incorrect; the TANGO II trial was a completed randomized clinical trial specifically in carbapenem-resistant infections (not the TANGO I urinary tract trial) and provided clinical outcome data, not merely pharmacokinetic-pharmacodynamic modeling.
Option D: Option D is incorrect; vaborbactam does not cover all four carbapenemase classes; its spectrum is limited to class A and class C serine enzymes.
Option E: Option E is incorrect; the TANGO II trial demonstrated superiority, not non-inferiority, of meropenem-vaborbactam over best available therapy; current guidelines do not rank ceftazidime-avibactam uniformly above meropenem-vaborbactam for KPC-CRE.
11. A Klebsiella pneumoniae isolate with intermediate carbapenem susceptibility is negative for KPC, NDM, VIM, IMP, and OXA-48 by PCR. Which combination of resistance mechanisms is the most established explanation for non-carbapenemase-mediated carbapenem resistance in this species?
A) Acquisition of a plasmid-encoded class A carbapenemase variant below standard PCR detection thresholds, combined with efflux pump upregulation via the AcrAB-TolC system that exports carbapenems faster than they can be replaced by diffusion
B) Chromosomal point mutation in the active site of PBP2 (penicillin-binding protein 2), producing a modified transpeptidase with reduced carbapenem binding affinity analogous to the PBP2a mechanism of methicillin-resistant Staphylococcus aureus
C) Complete loss of all outer membrane porins through a single deletion event, rendering the outer membrane impermeable to all hydrophilic antibiotics including carbapenems, aminoglycosides, and fluoroquinolones simultaneously
D) Upregulation of the MexAB-OprM efflux pump system, combined with AmpC overexpression from a chromosomal promoter mutation; both mechanisms together reduce periplasmic carbapenem concentrations below the PBP2 binding threshold
E) Loss or downregulation of outer membrane porins OmpK35 and OmpK36, combined with overexpression of ESBL or AmpC beta-lactamases; porin loss reduces carbapenem entry while ESBL/AmpC hydrolyzes the reduced amount of drug that does penetrate, producing synergistic resistance without a carbapenemase
ANSWER: E
Rationale:
Non-carbapenemase-mediated carbapenem resistance in Klebsiella pneumoniae is well characterized and results from the synergy of two independent resistance mechanisms that together achieve what neither accomplishes alone. The outer membrane porins OmpK35 and OmpK36 (homologs of OmpF and OmpC in E. coli) are the primary hydrophilic channels through which carbapenems diffuse from the extracellular space into the periplasm to reach their PBP targets. Loss or downregulation of these porins, typically through mutations in porin structural genes or regulatory elements, reduces carbapenem influx. However, porin loss alone generally produces only intermediate-level resistance because sufficient drug can still diffuse through the lipid bilayer or residual porin expression. When combined with ESBL (extended-spectrum beta-lactamase) or AmpC cephalosporinase overexpression, the small amount of carbapenem that does enter the periplasm is enzymatically hydrolyzed before it can reach PBPs, producing synergistic high-level resistance without any carbapenemase. These strains are carbapenemase-PCR-negative, as in the case described.
Option A: Option A is incorrect; while sub-threshold PCR variants are theoretically possible, the established and dominant mechanism of non-carbapenemase CRE is porin loss plus ESBL/AmpC — not undetected carbapenemase combined with efflux.
Option B: Option B is incorrect; PBP modification is the mechanism of methicillin resistance in staphylococci and is not the established mechanism of carbapenem resistance in Enterobacteriaceae, which have multiple PBPs and do not rely on a single PBP target modification.
Option C: Option C is incorrect; complete porin loss rarely occurs as a single event, and when it does it is not selective for carbapenems — however, the clinically characterized resistance mechanism requires the co-presence of enzymatic hydrolysis to achieve high-level resistance.
Option D: Option D is incorrect; MexAB-OprM is a Pseudomonas aeruginosa efflux system; Klebsiella uses the AcrAB-TolC system for efflux, but efflux pump upregulation alone is not the primary mechanism of carbapenem resistance in Klebsiella and is not what is described in non-carbapenemase CRE literature.
12. Sulbactam is used in combination with durlobactam (as sulbactam-durlobactam, marketed as Xacduro) for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Which property of sulbactam distinguishes it from other beta-lactamase inhibitors (clavulanate, tazobactam, avibactam, vaborbactam) in this clinical context?
A) Sulbactam is the only beta-lactamase inhibitor capable of inhibiting class D OXA-type carbapenemases; its unique thiazolidine ring structure fits into the OXA-23 and OXA-58 active sites in a manner that no other inhibitor achieves at standard doses
B) Sulbactam has a longer serum half-life than other beta-lactamase inhibitors, allowing it to maintain sufficient periplasmic concentrations in Acinetobacter biofilms throughout the dosing interval without the need for continuous infusion
C) Sulbactam possesses intrinsic antibacterial activity against Acinetobacter baumannii through direct binding to PBP1 and PBP3, independent of any beta-lactamase inhibitory function; this direct PBP-binding activity makes sulbactam itself a therapeutic agent against Acinetobacter, not merely a beta-lactamase inhibitor used to protect a partner drug
D) Sulbactam is the only beta-lactamase inhibitor that penetrates the outer membrane of Acinetobacter baumannii via TonB-dependent transporters, achieving periplasmic concentrations substantially higher than those reached by avibactam or vaborbactam in the same organism
E) Sulbactam uniquely inhibits the MBL (metallo-beta-lactamase) OXA-23 through a zinc-chelating side chain that is absent from other beta-lactamase inhibitors, making it the only agent capable of protecting a partner beta-lactam from OXA-23 hydrolysis
ANSWER: C
Rationale:
Sulbactam is categorically different from clavulanate, tazobactam, avibactam, and vaborbactam in one defining respect: it has intrinsic antibacterial activity against Acinetobacter baumannii through direct binding to PBP1 and PBP3 of the organism. All other beta-lactamase inhibitors in clinical use are pharmacologically inactive against bacteria on their own — they function exclusively as enzyme inhibitors protecting a partner beta-lactam. Sulbactam's direct PBP activity means that when used against Acinetobacter, sulbactam itself contributes to bactericidal killing by inhibiting cell wall synthesis, in addition to any beta-lactamase inhibitory function it may provide. However, CRAB strains produce OXA-type carbapenemases (OXA-23, OXA-58) that hydrolyze sulbactam, rendering it inactive as monotherapy. Durlobactam is a DBO inhibitor that protects sulbactam from OXA hydrolysis, allowing sulbactam's intrinsic anti-Acinetobacter PBP activity to be restored. This combination (sulbactam-durlobactam) is the first FDA-approved targeted agent specifically for CRAB.
Option A: Option A is incorrect; sulbactam does have some class D inhibitory activity but it is the PBP-binding antibacterial activity — not OXA inhibition superiority — that defines its role in CRAB therapy; durlobactam, not sulbactam, provides the OXA inhibition that makes the combination work.
Option B: Option B is incorrect; half-life is not the distinguishing pharmacological property that defines sulbactam's role in CRAB therapy; the critical distinction is its intrinsic antibacterial activity.
Option D: Option D is incorrect; sulbactam does not use TonB-dependent transporters for outer membrane penetration; that mechanism belongs exclusively to cefiderocol.
Option E: Option E is incorrect; OXA-23 is a class D serine carbapenemase, not a metallo-beta-lactamase (MBL); sulbactam does not chelate zinc and does not have a zinc-chelating side chain.
13. Aztreonam-avibactam is used for infections caused by NDM-producing organisms that are resistant to all carbapenems and to ceftazidime-avibactam. Which of the following correctly explains the pharmacological rationale for combining aztreonam with avibactam specifically against NDM producers?
A) Avibactam directly inhibits NDM by forming a covalent adduct with the enzyme's zinc cofactors, while aztreonam provides synergistic bactericidal activity by binding PBP3; the combination is necessary because aztreonam alone is hydrolyzed by NDM before reaching its PBP target
B) Aztreonam is hydrolyzed by NDM, but avibactam traps the aztreonam-NDM acyl-enzyme complex before complete ring opening, allowing aztreonam to dissociate intact and re-engage its PBP3 target in a cycling inhibitory mechanism
C) Aztreonam's siderophore conjugate moiety is activated only in the presence of avibactam; without avibactam, aztreonam cannot engage TonB-dependent transporters on NDM-producing organisms and therefore cannot penetrate the outer membrane to reach its target
D) Aztreonam is intrinsically stable to hydrolysis by NDM and other class B metallo-beta-lactamases, but NDM-producing organisms almost always co-produce serine beta-lactamases (ESBL, AmpC, KPC) that do hydrolyze aztreonam; avibactam inhibits these co-produced serine enzymes, protecting aztreonam so that its intrinsic NDM stability can be exploited for antibacterial effect
E) Avibactam inhibits NDM-mediated efflux pump upregulation in Klebsiella pneumoniae, preventing export of aztreonam from the periplasm; without avibactam, aztreonam is pumped out before it can bind PBP3 in NDM-producing strains
ANSWER: D
Rationale:
The aztreonam-avibactam combination exploits two distinct and complementary pharmacological properties. First, aztreonam is intrinsically resistant to hydrolysis by class B metallo-beta-lactamases including NDM, VIM, and IMP — a property attributed to the monocyclic beta-lactam ring structure, which is a poor substrate for the zinc-dependent hydrolytic mechanism of class B enzymes. Second, virtually all NDM-producing clinical isolates co-produce serine beta-lactamases (most commonly CTX-M-type ESBLs, AmpC, or occasionally KPC) encoded on the same resistance plasmid. These co-produced serine enzymes efficiently hydrolyze aztreonam, negating its intrinsic NDM stability when aztreonam is used alone. Avibactam, a DBO inhibitor of class A (KPC, ESBL), class C (AmpC), and some class D serine beta-lactamases, inhibits these co-produced enzymes without affecting NDM. The combination therefore presents NDM-producing bacteria with a drug (aztreonam) that NDM cannot hydrolyze, with the co-produced serine enzymes that would otherwise destroy aztreonam neutralized by avibactam. This is a division of pharmacological labor: avibactam handles the serine enzymes; aztreonam handles the NDM by virtue of being NDM-stable.
Option A: Option A is incorrect; avibactam does not inhibit NDM directly; NDM is a class B metallo-enzyme with no catalytic serine for avibactam to target.
Option B: Option B is incorrect; aztreonam does not form an acyl-enzyme complex with NDM at all — it is simply not hydrolyzed by NDM because the zinc-dependent mechanism cannot process the monocyclic beta-lactam efficiently.
Option C: Option C is incorrect; aztreonam is not a siderophore conjugate and does not use TonB-dependent transporters; that mechanism belongs to cefiderocol.
Option E: Option E is incorrect; avibactam does not inhibit efflux pumps; its mechanism is serine beta-lactamase inhibition, and efflux pump upregulation is not the primary mechanism by which aztreonam fails against NDM-producing strains.
14. Imipenem-cilastatin-relebactam is distinguished from meropenem-vaborbactam by a clinically important coverage advantage for one pathogen beyond KPC-CRE. Which of the following correctly identifies this advantage and explains its pharmacological basis?
A) Imipenem-relebactam has enhanced activity against multidrug-resistant Pseudomonas aeruginosa compared to meropenem-vaborbactam because relebactam (a DBO inhibitor) inhibits AmpC cephalosporinase overexpression — a key carbapenem resistance mechanism in Pseudomonas — while also covering KPC; this added AmpC inhibitory activity restores imipenem activity against Pseudomonas strains with AmpC-mediated carbapenem resistance
B) Imipenem-relebactam covers NDM-producing organisms that meropenem-vaborbactam does not, because relebactam's DBO scaffold has a zinc-chelating auxiliary group that vaborbactam's boronic acid scaffold lacks, enabling partial metallo-enzyme inhibition at achievable clinical concentrations
C) Imipenem-relebactam covers carbapenem-resistant Acinetobacter baumannii more reliably than meropenem-vaborbactam because relebactam inhibits OXA-23 and OXA-58 more potently than vaborbactam inhibits these class D carbapenemases
D) Imipenem-relebactam is preferred over meropenem-vaborbactam for urinary tract infections because relebactam achieves higher renal tubular concentrations than vaborbactam, maintaining inhibitory concentrations against KPC-CRE throughout the dosing interval at standard doses
E) Imipenem-relebactam covers ESBL-producing Enterobacteriaceae more reliably than meropenem-vaborbactam because relebactam's DBO scaffold achieves a lower Ki for CTX-M (cefotaxime-Munich enzyme)-type ESBLs than vaborbactam's boronic acid scaffold at the concentrations achieved in bloodstream infections
ANSWER: A
Rationale:
Relebactam is a diazabicyclooctane (DBO) inhibitor — in the same structural class as avibactam — with inhibitory activity against class A serine beta-lactamases (including KPC) and class C AmpC cephalosporinases. The AmpC inhibitory activity of relebactam is the pharmacological basis for imipenem-relebactam's enhanced spectrum against multidrug-resistant Pseudomonas aeruginosa. In Pseudomonas, carbapenem resistance frequently involves upregulation of chromosomally encoded AmpC (typically by loss of its negative regulator dacB or mrcB) in combination with OprD porin downregulation. Relebactam's inhibition of AmpC, combined with imipenem's intrinsic anti-Pseudomonas PBP activity, restores activity against Pseudomonas strains where AmpC overexpression is the primary carbapenem resistance mechanism. Meropenem-vaborbactam has less established activity against difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa) compared to imipenem-relebactam. This distinction is recognized in IDSA (Infectious Diseases Society of America) guidance on DTR-P. aeruginosa therapy.
Option B: Option B is incorrect; relebactam does not inhibit NDM or any class B metallo-beta-lactamase; the DBO scaffold has no zinc-chelating activity and cannot inhibit metallo-enzymes.
Option C: Option C is incorrect; neither relebactam nor vaborbactam reliably inhibits OXA-23 or OXA-58 type carbapenemases at standard clinical concentrations; neither combination is established therapy for CRAB, and coverage of CRAB is not the distinguishing advantage of imipenem-relebactam.
Option D: Option D is incorrect; renal tubular concentrations of relebactam versus vaborbactam are not the pharmacological basis for distinguishing these agents; the key coverage difference is Pseudomonas AmpC, not urinary concentrations.
Option E: Option E is incorrect; CTX-M ESBL inhibition is a shared property of all three DBO/boronic acid inhibitors; differential Ki for CTX-M between relebactam and vaborbactam is not the clinically established distinguishing feature between these combinations.
15. Carbapenems resist hydrolysis by most serine beta-lactamases (class A, C, and D) that readily inactivate penicillins and cephalosporins. Which structural feature is primarily responsible for this serine beta-lactamase stability, and what is the critical exception to carbapenem beta-lactamase resistance?
A) The C-1 carbon substitution (replacing sulfur at position 1 with carbon, creating the "carba" prefix) sterically blocks access of all serine and zinc-dependent beta-lactamases to the carbonyl carbon, conferring comprehensive resistance to enzymatic hydrolysis by all four Ambler classes
B) The trans-1-hydroxyethyl (1-beta-hydroxyethyl) substituent at C-6 creates steric hindrance that prevents most serine beta-lactamases from forming a productive acyl-enzyme intermediate; however, class B zinc-dependent metallo-beta-lactamases (NDM, VIM, IMP) use a zinc-activated water hydrolysis mechanism that bypasses this steric barrier, making carbapenems susceptible to class B enzymes
C) The trans-1-hydroxyethyl group at C-6 forms a reversible covalent bond with the serine residue of class A, C, and D beta-lactamases, permanently inactivating these enzymes in a suicide inhibitor mechanism; this mechanism does not extend to class B enzymes because they lack the serine target
D) The extended C-2 side chain common to all carbapenems occupies the R2 binding pocket of class A beta-lactamases with such high affinity that it competitively displaces the beta-lactam ring from the active site before hydrolysis can occur; class B enzymes are resistant to this competitive displacement because they use a different binding architecture
E) The fusion of the pyroline ring at C-1 creates a rigid bicyclic conformation that is recognized by serine beta-lactamases as a non-substrate inhibitor, trapping the enzyme in an unproductive complex; class B enzymes recognize the same conformation as a substrate due to their zinc-dependent catalytic geometry
ANSWER: B
Rationale:
The 1-beta-hydroxyethyl (trans-hydroxyethyl) substituent at C-6 of the carbapenem bicyclic ring is the primary structural basis for resistance to serine beta-lactamases. The bulky trans configuration of this group creates steric hindrance at the carbonyl carbon that impairs productive binding of class A (TEM, SHV, CTX-M, KPC), class C (AmpC), and class D (OXA-type) serine beta-lactamases to the beta-lactam ring — these enzymes require close approach of their catalytic serine to the carbonyl carbon to form the acyl-enzyme intermediate, and the hydroxyethyl group physically obstructs this approach. Class B metallo-beta-lactamases (NDM, VIM, IMP) hydrolyze the beta-lactam through an entirely different mechanism: zinc-coordinated water acts as a direct nucleophile attacking the carbonyl carbon without requiring the close serine-carbon approach needed by class A/C/D enzymes. The zinc-mediated mechanism is not impeded by the hydroxyethyl steric barrier, explaining why carbapenems are hydrolyzed by class B enzymes despite being resistant to most serine beta-lactamases. This is the pharmacological reason why NDM-producing organisms are resistant to all carbapenems.
Option A: Option A is incorrect; the C-1 carbon substitution is a defining feature of carbapenems but is not the primary mechanism of serine beta-lactamase resistance, and carbapenems are not resistant to class B enzymes — they are hydrolyzed by NDM, VIM, and IMP.
Option C: Option C is incorrect; the hydroxyethyl group does not form a covalent bond with serine beta-lactamases; it provides steric hindrance (a passive structural barrier), not active suicide inhibitor chemistry.
Option D: Option D is incorrect; the C-2 side chain varies among carbapenem agents (it is responsible for the anti-Pseudomonas activity of meropenem and imipenem) and is not the primary basis for serine beta-lactamase resistance; competitive active site displacement is not the established mechanism.
Option E: Option E is incorrect; the pyroline ring fusion is not a mechanism of enzyme trapping; carbapenems are not suicide inhibitors of serine beta-lactamases.
16. The CREDIBLE-CR trial (Carbapenem-Resistant and Difficult-to-Treat Infections — a non-randomized, open-label, pathogen-focused descriptive phase 3 trial comparing cefiderocol to best available therapy in carbapenem-resistant gram-negative infections) provided the pivotal clinical data supporting cefiderocol's approval. Which of the following accurately describes the key clinical safety finding from this trial that has influenced the clinical positioning of cefiderocol for CRAB infections?
A) The CREDIBLE-CR trial demonstrated that cefiderocol caused significantly higher rates of Clostridioides difficile-associated diarrhea than best available therapy across all pathogen subgroups, leading to a black-box warning against concurrent use with proton pump inhibitors in patients with CRAB infections
B) The CREDIBLE-CR trial found that cefiderocol-treated patients developed siderophore-mediated systemic iron depletion at a rate of approximately 40%, requiring therapeutic iron supplementation in the majority of patients receiving more than 7 days of therapy
C) The CREDIBLE-CR trial showed that cefiderocol caused clinically significant nephrotoxicity in patients with pre-existing renal impairment, with a rate of acute kidney injury more than twice that of best available therapy in the CRAB subgroup, leading to mandatory renal monitoring requirements
D) The CREDIBLE-CR trial demonstrated that cefiderocol achieved microbiological eradication in all pathogen subgroups but showed no clinical cure benefit over best available therapy in any subgroup, leading to its approval being restricted to salvage therapy only after failure of at least two prior regimens
E) The CREDIBLE-CR trial reported numerically higher all-cause mortality in the cefiderocol arm compared to the best available therapy arm specifically in patients with Acinetobacter baumannii infections; the mechanism of this mortality difference is not fully understood and remains under investigation, introducing clinical caution about cefiderocol as first-line monotherapy for CRAB
ANSWER: E
Rationale:
The CREDIBLE-CR trial (Bassetti et al., Lancet Infectious Diseases, 2021) was a non-randomized descriptive trial comparing cefiderocol to best available therapy in patients with serious infections caused by carbapenem-resistant gram-negative organisms. The trial confirmed cefiderocol's microbiological activity across multiple resistant pathogens. However, in the Acinetobacter baumannii patient subset — where best available therapy comparators included polymyxin-based regimens — all-cause mortality was numerically higher in the cefiderocol arm than in the best available therapy arm. This unexpected finding generated significant clinical attention because it raised the possibility that cefiderocol's in vitro activity against CRAB does not necessarily translate to superior clinical outcomes. Proposed explanations include higher baseline severity in the cefiderocol arm, limitations of the non-randomized design, and possible limitations of cefiderocol's bactericidal activity in vivo against Acinetobacter under certain clinical conditions. The finding did not result in withdrawal of cefiderocol's approval or a specific black-box warning for CRAB, but has led to caution about its routine use as first-line monotherapy for CRAB pending further data.
Option A: Option A is incorrect; the CREDIBLE-CR safety signal was not Clostridioides difficile colitis, and no black-box warning related to C. difficile or proton pump inhibitor interaction was issued based on this trial.
Option B: Option B is incorrect; siderophore-mediated iron depletion is not a recognized clinical adverse effect of cefiderocol therapy; the siderophore moiety functions as a bacterial iron-piracy delivery mechanism, not a systemic human iron chelator.
Option C: Option C is incorrect; the primary adverse finding in the CREDIBLE-CR Acinetobacter subset was all-cause mortality, not nephrotoxicity; nephrotoxicity was not the identified differentiating safety signal.
Option D: Option D is incorrect; the CREDIBLE-CR trial did not restrict cefiderocol's approval to salvage therapy after two prior failures; it received approval for gram-negative infections with limited treatment options, not a specific line-of-therapy restriction.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.